Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer
Details
Publication Year 2024-05-17,Volume 12,Issue #5,Page 1117
Journal Title
Biomedicines
Publication Type
Review
Abstract
Recent advances in the treatment of gastric cancer (GC) with chemotherapy, immunotherapy, anti-angiogenic therapy and targeted therapies have yielded some improvement in survival outcomes; however, metastatic GC remains a lethal malignancy and amongst the leading causes of cancer-related mortality worldwide. Importantly, the ongoing molecular characterisation of GCs continues to uncover potentially actionable molecular targets. Among these, aberrant FGFR2-driven signalling, predominantly arising from FGFR2 amplification, occurs in approximately 3-11% of GCs. However, whilst several inhibitors of FGFR have been clinically tested to-date, there are currently no approved FGFR-directed therapies for GC. In this review, we summarise the significance of FGFR2 as an actionable therapeutic target in GC, examine the recent pre-clinical and clinical data supporting the use of small-molecule inhibitors, antibody-based therapies, as well as novel approaches such as proteolysis-targeting chimeras (PROTACs) for targeting FGFR2 in these tumours, and discuss the ongoing challenges and opportunities associated with their clinical development.
Publisher
MDPI
Keywords
Fgfr2; gastric cancer; monoclonal antibodies; targeted therapies
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.3390/biomedicines12051117
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-07-11 06:58:36
Last Modified: 2024-07-11 07:07:57

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙